Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia.
J Oncol Pharm Pract
; 22(2): 354-6, 2016 Apr.
Article
em En
| MEDLINE
| ID: mdl-25567519
ABSTRACT
Palifermin and pegaspargase are Escherichia coli-derived drug products. Hypersensitivity reactions, including anaphylaxis, are frequently reported with pegaspargase. In high-risk acute lymphoblasic leukemia (ALL), patients undergoing allogeneic hematopoietic stem cell transplant may be treated with palifermin as a supportive care measure for mucositis prophylaxis. However, no literature exists documenting the cross-reactivity between palifermin and pegaspargase. We report a case in which a child with very high-risk ALL having experienced severe anaphylaxis with pegaspargase was later successfully treated with palifermin during stem cell transplant conditioning.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polietilenoglicóis
/
Asparaginase
/
Índice de Gravidade de Doença
/
Fator 7 de Crescimento de Fibroblastos
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Anafilaxia
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
Limite:
Child, preschool
/
Humans
/
Male
Idioma:
En
Revista:
J Oncol Pharm Pract
Assunto da revista:
FARMACIA
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Estados Unidos